Recurrent Left Ventricular Thrombus Formation on Rivaroxaban Therapy in Cardiomyopathy and Liver Cirrhosis

Usman Ghani; Karlo A Wiley; Raman Singhal; Cristina Sanina

doi:10.1016/j.jaccas.2020.05.094

Recurrent Left Ventricular Thrombus Formation on Rivaroxaban Therapy in Cardiomyopathy and Liver Cirrhosis

JACC Case Rep. 2020 Aug 19;2(10):1501-1504. doi: 10.1016/j.jaccas.2020.05.094. eCollection 2020 Aug.

Authors

Usman Ghani¹, Karlo A Wiley², Raman Singhal¹, Cristina Sanina³

Affiliations

¹ Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
² College of Agriculture and Life Science, Cornell University, Ithaca, New York.
³ Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Abstract

Left ventricular (LV) thrombus in patients with reduced LV systolic function carries significant thromboembolic risk. Direct oral anticoagulants are an attractive alternative to warfarin for LV thrombus management. However, there are not enough data regarding the safety and efficacy of direct oral anticoagulants for the treatment of LV thrombus. (Level of Difficulty: Beginner.).

Keywords: DOAC, direct oral anticoagulant; LV thrombus; LV, left ventricular; cirrhosis; oral anticoagulation; rivaroxaban.

Publication types

Case Reports